USANA Health Sciences (NYSE:USNA) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• USANA Health Sciences has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, with several other analysts also indicating a negative outlook.
• The company's stock price has fallen 22.9%, closing at $20.22, significantly below its 50-day moving average of $29.63.
• Insider transactions indicate a decrease in ownership, with key executives selling significant shares of the stock in recent months.

USANA Health Sciences (NYSE:USNA - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Several other research analysts have also recently issued reports on USNA. Weiss Ratings reiterated a "sell (d+)" rating on shares of USANA Health Sciences in a report on Wednesday. Zacks Research cut shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Monday, September 22nd. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $36.00.

USANA Health Sciences Trading Down 22.9%

NYSE USNA opened at $20.22 on Friday. The company's 50-day moving average price is $29.63 and its 200-day moving average price is $29.29. The stock has a market cap of $369.42 million, a PE ratio of 11.23, a PEG ratio of 0.83 and a beta of 0.61. USANA Health Sciences has a 12 month low of $20.10 and a 12 month high of $41.83.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Thursday, October 9th. The company reported $0.56 EPS for the quarter. The firm had revenue of $200.22 million for the quarter. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. As a group, sell-side analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Transactions at USANA Health Sciences

In other news, insider David Mulham Mulham sold 3,515 shares of the firm's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total value of $106,363.90. Following the sale, the insider directly owned 9,260 shares in the company, valued at approximately $280,207.60. This trade represents a 27.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. 0.63% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its position in shares of USANA Health Sciences by 339.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after purchasing an additional 771 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after purchasing an additional 1,901 shares during the last quarter. CWM LLC raised its position in shares of USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company's stock valued at $84,000 after purchasing an additional 1,445 shares during the last quarter. AlphaQuest LLC raised its position in shares of USANA Health Sciences by 300.9% in the 1st quarter. AlphaQuest LLC now owns 3,412 shares of the company's stock valued at $92,000 after purchasing an additional 2,561 shares during the last quarter. Finally, Quantbot Technologies LP raised its position in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock valued at $121,000 after purchasing an additional 646 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.